OPKO Health (OPK) Reports In-Line Q4 EPS

Go back to OPKO Health (OPK) Reports In-Line Q4 EPS

OPKO Announces Financial and Operating Results

February 29, 2016 4:16 PM EST

Consolidated Revenue Increased to $276.2 Million From $25.5 Million for the Three Months Ended December 31, 2015, and Increased to $491.7 Million from $91.1 Million for the Year Ended December 31, 2015 Clinical Utility Study Demonstrates 4Kscore® Test Reduces Number of Unnecessary Prostate Biopsies While Improving Risk Prediction for Aggressive Prostate Cancer 4Kscore Blood Test to Identify Risk of Aggressive Prostate Cancer Assigned Level 1 CPT Code Rayaldee PDUFA Date Remains on Track For March 29, 2016 Topline Phase 3 Results for hGH-CTP in Adults Expected 2H 2016; Pediatric Phase 3... More

OPKO's GeneDx Recognizes International Rare Disease Day with Donation of Free Exome Tests to Syndromes Without a Name

February 29, 2016 8:30 AM EST

OTSEGO, Mich. and MIAMI, Feb. 29, 2016 /PRNewswire/ -- OPKO Health, Inc. (NYSE: OPK) through its GeneDx subsidiary and Syndromes Without a Name (SWAN) are proud to announce the donation of five Whole Exome Sequencing (WES) Trio tests to SWAN on Rare Disease Day as a way to honor the company's founding principles. Rare Disease Day, which takes place on the last day of February each year, aims to raise awareness about rare and ultra-rare diseases and the impact that they have on patients' lives.

"As a laboratory founded to... More